PCSK9 and familial hypercholesterolemia: Recent data showed that in patients with familiar hypercholesterolemia anti-PCSK9 mAb treatment inhibits platelet reactivity but it is unclear if this effect is mediated by a direct interaction between PCSK9 and platelets or by LDL lowering [6].